RX Biosyent Inc

BioSyent Pharma Receives Health Canada Approval to Market New Urgent Care Product

TORONTO, ONTARIO--(Marketwired - Jun 12, 2014) - BioSyent Inc. ("BioSyent") (TSX-VENTURE:RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has received Health Canada - Therapeutics Products Directorate approval to market a new urgent care product. This is the first of two products that were in-licensed from a European partner and submitted to Health Canada in 2013 for approval.

The newly approved urgent care drug is supplied in a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies and will be marketed by BioSyent Pharma's Hospital Division. It is anticipated that this new product will be launched in late 2014 or early 2015. "In anticipation of Health Canada approval our commercial team has started the launch preparation process for this new product," said René Goehrum, President and CEO of BioSyent. "We have already started discussions with key opinion leaders and other decision makers in the Canadian hospital market." Further product details will be disclosed closer to the launch date.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,801,195 shares issued and outstanding.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

BioSyent Inc.Mr. Rene C. GoehrumPresident and CEO(905) 206-0013investors@biosyent.comwww.biosyent.com